Tech East would like to invite you to participate in one of two interactive roundtable sessions focused on developing...
Artificial Intelligence (AI) research project aims to personalise prevention and treatments for heart failure.
World leading AI pioneer, Orbital Global, is proud to announce that it is a member of a new Horizon Europe research and innovation consortium, which aims to personalise prevention and treatment of cardiovascular diseases. Led by Novo Nordisk and Maastricht University, the ‘iCARE4CVD’ (individualised care from early risk of cardiovascular disease to established heart failure) consortium is formed of thirty-three leading international partners from civil society, academia, and industry.
Over the next four years, these organisations will work together to better understand cardiovascular diseases and optimise future prevention and treatment. By creating one database consisting of data from more than 1 million patients and using artificial intelligence, partners will look for new strategies to shift from a one-size-fits-all approach to personalised care.
Cardiovascular (CVD) disease is very prevalent worldwide with enormous socio-economic impact. It is still the most common cause of death, despite significant advantages in therapy. Due to population ageing and unhealthy lifestyle, the number of Europeans suffering from CVD currently exceeds 85 million and is still on the rise. This underscores the critical need for better care pathways to reduce the impact of CVD.
To improve patient outcomes, iCARE4CVD aims to improve four aspects of current care: 1) early diagnosis and classification into clinically meaningful subgroups; 2) risk stratification defining urgency for intervention; 3) prediction of individual treatment response; and 4) inclusion of outcomes based on patient’s perspective.
Orbital Global will harness its pioneering digital health research capabilities and its world-leading spin-out AI technology, VirtTuri® to help automate future treatments and improve prognoses. VirtTuri is a patented, regulatory compliant AI clinical informatics platform that deploys interactive hyperrealistic avatars to significantly enhance patient understanding of critical healthcare information. Proven to elevate user engagement and recall of complex healthcare information, the VirtTuri AI platform will embed within the clinical interface, providing user friendly real-time clinical information and interaction with patients.
Peter Brady, CEO of Orbital Global, comments: ‘Cardiovascular diseases affect 620 million people across the world and account for around 1 in 3 deaths globally.i Despite individual differences in risk factors and symptoms, there is currently a standard treatment plan for all patients. Our vision is to deploy VirtTuri within this project, to better understand patients’ individual needs and configure tailored treatments in real time for them, ultimately saving lives.’